The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:2169-2170 November 27, 2003 Number 22
NextNext

Enfuvirtide for Prophylaxis against HIV Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
-PubMed Citation
To the Editor: In their letter to the editor, Ferranti and Menichetti (Aug. 21 issue)1 propose that enfuvirtide "should be considered for prophylaxis against HIV-1 [human immunodeficiency virus type 1] infection in cases of high-risk exposure to a patient with multidrug-resistant virus." To be useful as part of a prophylactic strategy, drugs have to be easy to administer and inexpensive, have few side effects, and have proven efficacy.2 Enfuvirtide is not easy to administer (requiring two injections per day and 45 minutes of preparation), is in permanently short supply because of technical complexity, has at least mild side effects (there . . . [Full Text of this Article]


Related Letters:

Enfuvirtide for Prophylaxis against HIV Infection
Ferranti S., Menichetti F.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:815, Aug 21, 2003. Correspondence


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.